BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26029453)

  • 21. Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.
    Rasola C; Laurent-Puig P; André T; Falcoz A; Lepage C; Aparicio T; Bouché O; Lievre A; Mineur L; Bennouna J; Louvet C; Bachet JB; Borg C; Vernerey D; Lonardi S; Taieb J
    Eur J Cancer; 2023 Nov; 194():113321. PubMed ID: 37797388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer.
    Snyder RA; Hu CY; Cuddy A; Francescatti AB; Schumacher JR; Van Loon K; You YN; Kozower BD; Greenberg CC; Schrag D; Venook A; McKellar D; Winchester DP; Chang GJ;
    JAMA; 2018 May; 319(20):2104-2115. PubMed ID: 29800181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
    Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
    Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive Follow-Up After Curative Surgery for Colorectal Cancer.
    Rodrigues RV; Pereira da Silva J; Rosa I; Santos I; Pereira N; Soares C; Pereira AD
    Acta Med Port; 2017 Sep; 30(9):633-641. PubMed ID: 29025530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.
    Bergquist JR; Thiels CA; Spindler BA; Shubert CR; Hayman AV; Kelley SR; Larson DW; Habermann EB; Pemberton JH; Mathis KL
    Dis Colon Rectum; 2016 Dec; 59(12):1142-1149. PubMed ID: 27824699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
    Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
    J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does Advanced Imaging Have a Role in Detecting Local Recurrence of Soft-tissue Sarcoma?
    England P; Hong Z; Rhea L; Hirbe A; McDonald D; Cipriano C
    Clin Orthop Relat Res; 2020 Dec; 478(12):2812-2820. PubMed ID: 32667755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Causes of mortality in elderly UICC stage III colon cancer (CC) patients--Tumor-related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry.
    Nöpel-Dünnebacke S; Jütte H; Denz R; Feder IS; Kraeft AL; Lugnier C; Teschendorf C; Collette D; Böhner H; Engel L; Mueller L; Hartmann F; Kaiser U; Bruch HR; Hollerbach S; Arnold D; Timmesfeld N; Tannapfel A; Reinacher-Schick A
    Cancer Med; 2022 Apr; 11(8):1735-1744. PubMed ID: 35146948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients.
    Zhou C; Lu L; Huang Q; Tang Z; Tang R; Xiao Z; Xiao S
    BMC Gastroenterol; 2023 Apr; 23(1):110. PubMed ID: 37020295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy.
    Wong SK; Gondara L; Renouf DJ; Lim HJ; Loree JM; Davies JM; Gill S
    J Gastrointest Oncol; 2021 Apr; 12(2):446-454. PubMed ID: 34012638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
    Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
    Rosati G; Galli F; Cantore M; Bergamo F; Banzi M; Zampino MG; Mattioli R; Cardellino GG; Ronzoni M; Di Bartolomeo M; Tamberi S; Marchetti P; Rimassa L; Corsi D; Bochicchio AM; Artioli F; Labianca R; Galli F; Rulli E; Bilancia D; Bregni G;
    Oncologist; 2020 Jun; 25(6):e928-e935. PubMed ID: 31943506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
    Li T; Jia DD; Teng LS
    Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis.
    Breadner D; Loree JM; Cheung WY; Gipson M; Lakkunarajah S; Mulder KE; Spartlin JL; Kong S; Ding PQ; Gill S; Welch SA
    BMC Cancer; 2022 Nov; 22(1):1119. PubMed ID: 36319973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
    Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
    Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis.
    Zola P; Fuso L; Mazzola S; Piovano E; Perotto S; Gadducci A; Galletto L; Landoni F; Maggino T; Raspagliesi F; Sartori E; Scambia G
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S150-4. PubMed ID: 17868785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
    Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
    BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
    Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
    Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.